These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36777426)

  • 21. Urgency and Its Association With Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis.
    Sninsky JA; Barnes EL; Zhang X; Long MD
    Am J Gastroenterol; 2022 May; 117(5):769-776. PubMed ID: 35169109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52.
    Johnson T; Steere B; Zhang P; Zang Y; Higgs R; Milch C; Reinisch W; Panés J; Huang K; D'Haens G; Krishnan V
    Clin Transl Gastroenterol; 2023 Nov; 14(11):e00630. PubMed ID: 37594044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient interpretations of patient-reported outcome measures to assess bowel urgency: qualitative interviews in ulcerative colitis.
    Jairath V; Gibble TH; Moses R; Klooster B; Litcher-Kelly L; Walker M; Bernstein MC; Rupinski K; McLafferty M; Travis S; Dubinsky M
    J Patient Rep Outcomes; 2024 May; 8(1):54. PubMed ID: 38819757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis).
    Probert CS; Sebastian S; Gaya DR; Hamlin PJ; Gillespie G; Rose A; Tate H; Wheeler C; Irving PM
    BMJ Open Gastroenterol; 2018; 5(1):e000212. PubMed ID: 30002864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn's disease in adults with moderate-to-severe disease.
    Nag A; Romero B
    Health Qual Life Outcomes; 2022 May; 20(1):75. PubMed ID: 35525935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early resolution of bowel urgency by budesonide foam enema results in improved quality of life in patients with ulcerative colitis: a multicenter prospective observational study.
    Kobayashi T; Moriya K; Fujii T; Bamba S; Shinzaki S; Yamada A; Hisabe T; Sagami S; Hibiya S; Amano T; Takatsu N; Inagaki K; Iwayama KI; Hibi T
    Intest Res; 2024 Jul; ():. PubMed ID: 39004512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P075 Urgency and its Association with Quality of Life and Clinical Outcomes in Ulcerative Colitis Patients.
    Sninsky J; Barnes E; Zhang X; Long M
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S19-S20. PubMed ID: 37461991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabis for the treatment of ulcerative colitis.
    Kafil TS; Nguyen TM; MacDonald JK; Chande N
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An evaluation of mirikizumab for the treatment of ulcerative colitis.
    White C; Irving PM
    Expert Opin Biol Ther; 2024 Nov; 24(11):1199-1206. PubMed ID: 39360778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
    Danese S; Sands BE; Abreu MT; O'Brien CD; Bravatà I; Nazar M; Miao Y; Wang Y; Rowbotham D; Leong RWL; Arasaradnam RP; Afif W; Marano C
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2858-2867.e5. PubMed ID: 35276329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults.
    Dubinsky MC; Irving PM; Panaccione R; Naegeli AN; Potts-Bleakman A; Arora V; Shan M; Travis S
    J Patient Rep Outcomes; 2022 Apr; 6(1):31. PubMed ID: 35362902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark
    Gastroenterol Hepatol (N Y); 2019 May; 15(5 Suppl 2):1-24. PubMed ID: 31632213
    [No Abstract]   [Full Text] [Related]  

  • 36. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fecal urgency and incontinence in inflammatory bowel disease perceived by physician and patient: Results from the Swiss fecal urgency survey.
    Wespi N; Vavricka S; Brand S; Aepli P; Burri E; Misselwitz B; Seibold F; Hruz P; Peyrin-Biroulet L; Schoepfer A; Biedermann L; Sokollik C; Rogler G; Greuter T
    United European Gastroenterol J; 2024 Sep; ():. PubMed ID: 39246002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term effect of gluten-free diet on disease severity, quality of life, and inflammatory markers among patients with mild to moderate ulcerative colitis: A triple-blind randomized placebo-controlled trial.
    Alborzi Avanaki F; Ebrahimi Daryani N; Aletaha N; Hesabgar N; Rezaee-Zavareh MS; Hadi R
    Arab J Gastroenterol; 2024 May; ():. PubMed ID: 38714473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.
    Feagan BG; Lasch K; Lissoos T; Cao C; Wojtowicz AM; Khalid JM; Colombel JF
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):130-138.e7. PubMed ID: 29857145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    Panés J; Vermeire S; Lindsay JO; Sands BE; Su C; Friedman G; Zhang H; Yarlas A; Bayliss M; Maher S; Cappelleri JC; Bushmakin AG; Rubin DT
    J Crohns Colitis; 2018 Jan; 12(2):145-156. PubMed ID: 29028981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.